WO1998019160A3 - VERFAHREN ZUR INDIREKTEN BESTIMMUNG DER TYP I INTERFERON-PRODUKTION IN VIVO MITTELS ANTIKÖRPER GEGEN HUMANE Mx-PROTEINE SOWIE ANTIKÖRPER HIERZU - Google Patents

VERFAHREN ZUR INDIREKTEN BESTIMMUNG DER TYP I INTERFERON-PRODUKTION IN VIVO MITTELS ANTIKÖRPER GEGEN HUMANE Mx-PROTEINE SOWIE ANTIKÖRPER HIERZU Download PDF

Info

Publication number
WO1998019160A3
WO1998019160A3 PCT/DE1997/002536 DE9702536W WO9819160A3 WO 1998019160 A3 WO1998019160 A3 WO 1998019160A3 DE 9702536 W DE9702536 W DE 9702536W WO 9819160 A3 WO9819160 A3 WO 9819160A3
Authority
WO
WIPO (PCT)
Prior art keywords
type
directed against
interferon
antibodies directed
human proteins
Prior art date
Application number
PCT/DE1997/002536
Other languages
English (en)
French (fr)
Other versions
WO1998019160A2 (de
Inventor
Wussow Peter Von
Original Assignee
Wussow Peter Von
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wussow Peter Von filed Critical Wussow Peter Von
Priority to US09/297,475 priority Critical patent/US6200559B1/en
Priority to DE59712847T priority patent/DE59712847D1/de
Priority to EP97948699A priority patent/EP0937254B1/de
Publication of WO1998019160A2 publication Critical patent/WO1998019160A2/de
Publication of WO1998019160A3 publication Critical patent/WO1998019160A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4715—Cytokine-induced proteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur indirekten Bestimmung der Interferon-Produktion unter Verwendung von Antikörpern gegen MxA und/oder MxB sowie die Verwendung von Interferon bzw. Anti-Interferon-Mitteln zur Einstellung eines bestimmten MxA- oder MxB-Spiegels.
PCT/DE1997/002536 1996-10-31 1997-10-31 VERFAHREN ZUR INDIREKTEN BESTIMMUNG DER TYP I INTERFERON-PRODUKTION IN VIVO MITTELS ANTIKÖRPER GEGEN HUMANE Mx-PROTEINE SOWIE ANTIKÖRPER HIERZU WO1998019160A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/297,475 US6200559B1 (en) 1996-10-31 1997-10-31 Use of antibodies against MxA or MxB to determine levels of type I interferons in vivo
DE59712847T DE59712847D1 (de) 1996-10-31 1997-10-31 Monoklonaler Antikörper gegen MxA und MxB
EP97948699A EP0937254B1 (de) 1996-10-31 1997-10-31 Monoklonaler Antikörper gegen MxA und MxB

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19645010 1996-10-31
DE19645010.1 1996-10-31

Publications (2)

Publication Number Publication Date
WO1998019160A2 WO1998019160A2 (de) 1998-05-07
WO1998019160A3 true WO1998019160A3 (de) 1998-06-25

Family

ID=7810358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/002536 WO1998019160A2 (de) 1996-10-31 1997-10-31 VERFAHREN ZUR INDIREKTEN BESTIMMUNG DER TYP I INTERFERON-PRODUKTION IN VIVO MITTELS ANTIKÖRPER GEGEN HUMANE Mx-PROTEINE SOWIE ANTIKÖRPER HIERZU

Country Status (5)

Country Link
US (1) US6200559B1 (de)
EP (1) EP0937254B1 (de)
AT (1) ATE363072T1 (de)
DE (2) DE59712847D1 (de)
WO (1) WO1998019160A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033667A2 (en) * 2001-10-18 2003-04-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of mx gtpases in the prognosis and treatment of cancer
KR20050040866A (ko) * 2002-06-11 2005-05-03 아이다호 리서치 파운데이션 바이러스 감염의 검출을 위한 ⅰ형 인터페론-유도성 단백질
US20130196310A1 (en) 2008-05-20 2013-08-01 Rapid Pathogen Screening, Inc. Method and Device for Combined Detection of Viral and Bacterial Infections
US10808287B2 (en) 2015-10-23 2020-10-20 Rapid Pathogen Screening, Inc. Methods and devices for accurate diagnosis of infections
WO2018132673A1 (en) * 2017-01-13 2018-07-19 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating graft-versus-host disease
RS61621B1 (sr) * 2017-11-22 2021-04-29 Dewact Labs GmbH Postupak i sredstvo za međusobno razlikovanje virusnih i bakterijskih infekcija
CN116063536B (zh) * 2022-10-24 2023-07-25 保定国兰生物技术有限公司 抗人MxA单克隆抗体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024500A1 (en) * 1994-03-10 1995-09-14 Ciba Corning Diagnostics Corp. Inhibition of protease activity of human whole blood cell lysates
EP0725081A1 (de) * 1994-08-08 1996-08-07 Kyowa Hakko Kogyo Co., Ltd. MONOKLONALER ANTIKÖRPER GEGEN MxA DES MENSCHLICHEN Mx PROTEINS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466585A (en) * 1986-04-15 1995-11-14 Ciba-Geigy Corporation Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024500A1 (en) * 1994-03-10 1995-09-14 Ciba Corning Diagnostics Corp. Inhibition of protease activity of human whole blood cell lysates
EP0725081A1 (de) * 1994-08-08 1996-08-07 Kyowa Hakko Kogyo Co., Ltd. MONOKLONALER ANTIKÖRPER GEGEN MxA DES MENSCHLICHEN Mx PROTEINS

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HORISBERGER M.A ET AL: "IFN alpha induced human 78kD protein: purification and homologies with the mouse Mx protein, production of monoclonal antibodies and potentiation effect of IFN gamma", J.INTERFERON RES., vol. 7, no. 4, 1987, pages 331 - 343, XP002061585 *
OH S-K ET AL: "Quantitation of interferon-induced Mx protein in whole blood lysates by an immunochemiluminescent assay: Elimination of protease activity of cell lysates in toto.", JOURNAL OF IMMUNOLOGICAL METHODS 176 (1). 1994. 79-91. ISSN: 0022-1759, XP002059944 *
STAEHELI, PETER ET AL: "Polyclonal and monoclonal antibodies to the interferon-inducible protein Mx of influenza virus-resistant mice", J.BIOL.CHEM., vol. 260, no. 3, 1985, pages 1821 - 1825, XP002061587 *
TOWBIN H ET AL: "A WHOLE BLOOD IMMUNOASSAY FOR THE INTERFERON-INDUCIBLE HUMAN MX PROTEIN.", J INTERFERON RES 12 (2). 1992. 67-74. CODEN: JIREDJ ISSN: 0197-8357, XP002059945 *
WÜTHRICH, RÜDI ET AL: "Monoclonal antibodies detect protein Mx in cells of interferon treated influenza virus resistant cells", BIOL.INTERFERON SYST.PROC. TNO-ISIR (MEETING 1984), 1985, pages 317 - 323, XP002061586 *

Also Published As

Publication number Publication date
EP0937254B1 (de) 2007-05-23
EP0937254A2 (de) 1999-08-25
DE19748287A1 (de) 1999-01-07
DE59712847D1 (de) 2007-07-05
WO1998019160A2 (de) 1998-05-07
ATE363072T1 (de) 2007-06-15
US6200559B1 (en) 2001-03-13

Similar Documents

Publication Publication Date Title
NO2017038I2 (no) Adalimumab - Forlenget SPC
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
WO2003060090A3 (en) Novel cytokine zcytor17 ligand
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
MY145191A (en) Human antibodies that bind human il-12 and methods for producing
ATE474052T1 (de) Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
IL100731A0 (en) Mixed specificity fusion protein and pharmaceutical composition containing it
HUP9900920A2 (hu) Eljárás emlőssejt-tenyészetekben termelt proteinek szializációjának szabályozására
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
WO1998019160A3 (de) VERFAHREN ZUR INDIREKTEN BESTIMMUNG DER TYP I INTERFERON-PRODUKTION IN VIVO MITTELS ANTIKÖRPER GEGEN HUMANE Mx-PROTEINE SOWIE ANTIKÖRPER HIERZU
ATE201994T1 (de) Mittel und methoden zur verbesserung der keratinocytenadhäsion an der haut
IL128569A0 (en) Fibroblast growth factor homologous factor S(FHFs) and methods of use
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
DE60042273D1 (de) Antitumorantikörper, proteine und deren verwendung
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
Vasil'ev et al. Biosynthesis of embryonic prealbumin by cultured human fibroblasts
AU2525597A (en) Monoclonal antibodies binding human growth hormone (hgh)
UA84540C2 (en) Novel cytokine zcytor17 ligand
MX343996B (es) Anticuerpos humanos que ligan el tnfa humano.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997948699

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997948699

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09297475

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 1997948699

Country of ref document: EP